Previous 10 | Next 10 |
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
The following slide deck was published by Royalty Pharma plc in conjunction with this event. For further details see: Royalty Pharma (RPRX) MorphoSys Transaction Call
Shares of MorphoSys (NASDAQ: MOR) sank 11.5% this week as of the market close on Thursday. The decline stemmed from the German drugmaker's announcement on Wednesday that it plans to acquire Constellation Pharmaceuticals (NASDAQ: CNST) for $1.7 billion. MorphoSys also said th...
Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation Pharmaceuticals Investment is anchored by royalties on Janssen’s Tremfya Partnership also includes royalties on four development-stage therapies, Developme...
The following slide deck was published by Royalty Pharma plc in conjunction with this event. For further details see: Royalty Pharma (RPRX) Presents At UBS Global Healthcare Virtual Conference - Slideshow
The following slide deck was published by Royalty Pharma plc in conjunction with this event. For further details see: Royalty Pharma (RPRX) Presents At the 7th Annual Truist Securities Life Sciences Summit - Slideshow
The following slide deck was published by Royalty Pharma plc in conjunction with this event. For further details see: Royalty Pharma (RPRX) Presents At Bank of America Merill Lynch Virtual Healthcare Conference - Slideshow
Image source: The Motley Fool. Repros Therapeutics (NASDAQ: RPRX) Q1 2021 Earnings Call May 11, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Repros Therapeutics (RPRX) Q1 2021 Earnings Call Transcript
The following slide deck was published by Royalty Pharma plc in conjunction with their 2021 Q1 earnings call. For further details see: Royalty Pharma plc 2021 Q1 - Results - Earnings Call Presentation
Royalty Pharma plc (RPRX) Q1 2021 Earnings Conference Call May 11, 2021 08:00 ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and Chief Executive Officer Marshall Urist - Executive Vice President and Co-He...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...